Respiratory syncytial virus (RSV) is a common respiratory virus which disproportionally affects new-borns and infants.

ECDC advocates for execution of respiratory syncytial virus (RSV) immunization programs including maternal vaccines to protect infants from severe hospitalization.

The United States may be headed for a rough flu season, with a virus that causes more severe symptoms than the one last year ...

Nirsevimab is a long-acting monoclonal antibody that provides season-long protection against RSV in infants, reducing ...

Department of Health’s Center for Health Development Cordillera (DOH-CHD-CAR) has reported progress in monitoring respiratory illnesses, and urged the public to stay vigilant and help keep case ...

China's National Disease Control and Prevention Administration warned on Monday of a general uptick in acute respiratory ...

Vaccination during pregnancy shows about 70% to 80% effectiveness in protecting newborns through antibody transfer. For adults over 60, vaccines demonstrate roughly 75% real-world effectiveness ...

Pfizer’s respiratory syncytial virus vaccine was more than 90% effective among older adults during the first season it was available, including among those with underlying conditions or severe disease ...

Artificial intelligence (AI) and “protein language” models can speed the design of monoclonal antibodies that prevent or reduce the severity of potentially life-threatening viral infections, according ...

New details from health officials suggest the whooping cough surge may be part of a national pattern driven by slipping ...